External pharmaceutical preparation for preventing and treating rheumatoid arthritis

Abstract

The invention discloses an external pharmaceutical preparation for preventing and treating rheumatoid arthritis. The external pharmaceutical preparation contains nabumetone, a mixture of azone and rhizoma chuanxiong oil, hydroxypropyl methyl cellulose and pharmaceutically acceptable other auxiliary additive components, wherein nabumetone is taken as an effective pharmaceutical component, the mixture of azone and rhizoma chuanxiong oil is taken as a transdermal agent, the hydroxypropyl methyl cellulose is taken as a matrix, the mass content of the transdermal agent is 0.5%-10%, and the mass ratio of azone to rhizoma chuanxiong oil is (0.01-5) to 1. According to the external pharmaceutical preparation, the hydroxypropyl methyl cellulose is taken as the matrix, rhizoma chuanxiong oil and azone can generate a synergistic interaction effect on promoting nabumetone to penetrate through skin when being commonly taken as the transdermal agent, and particularly, the synergistic interaction effect is remarkably improved when rhizoma chuanxiong oil and azone are in the proportion range of the invention.

Description

technical field [0001] The invention relates to the field of medicine, more specifically, the invention relates to an external pharmaceutical preparation for preventing and treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (Rheumatoid Arthritis, RA, the same below) is an autoimmune disease mainly manifested by chronic inflammatory lesions of synovial joints, and the incidence rate in my country is about 0.32%-0.36%. Drug therapy for RA patients mainly includes two aspects: analgesia and disease-modifying treatment. Analgesics, non-steroidal anti-inflammatory drugs (NSAIDs, the same below), and glucocorticoids mainly achieve the purpose of relieving joint pain in patients. The benefits of this treatment are short-term and can only be used as adjuvant therapy, which makes RA patients The main treatment for long-term benefits is to use disease-modifying drugs. NSAIDs mainly inhibit the activity of cyclooxygenase (Cyclooxygenase, COX, the same be...

AI Technical Summary

Problems solved by technology

Although the topical preparation can reduce the incidence of adverse reactions to a certain extent compared with oral preparations, and can specifically target local lesions, its single dose is limited and the drug release time is short, which will lead to an increase in the frequency of daily administration , and the drug concentration in the body fluctuates greatly, which is not optimal for reducing the incidence of adverse reactions, and is not conducive to the sustained and stable performance of the drug effect

Images